These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 20226548)

  • 1. Argatroban for elective percutaneous coronary intervention: the ARG-E04 multi-center study.
    Rössig L; Genth-Zotz S; Rau M; Heyndrickx GR; Schneider T; Gulba DC; Desaga M; Buerke M; Harder S; Zeiher AM;
    Int J Cardiol; 2011 Apr; 148(2):214-9. PubMed ID: 20226548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of body mass index on Argatroban therapy during percutaneous coronary intervention.
    Hursting MJ; Jang IK
    J Thromb Thrombolysis; 2008 Jun; 25(3):273-9. PubMed ID: 17530465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What is the optimal anticoagulation level with argatroban during percutaneous coronary intervention?
    Cruz-Gonzalez I; Sanchez-Ledesma M; Osakabe M; Watanabe H; Baron SJ; Healy JL; Yeh RW; Jang IK
    Blood Coagul Fibrinolysis; 2008 Jul; 19(5):401-4. PubMed ID: 18600089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticoagulation with argatroban for elective percutaneous coronary intervention: population pharmacokinetics and pharmacokinetic-pharmacodynamic relationship of coagulation parameters.
    Akimoto K; Klinkhardt U; Zeiher A; Niethammer M; Harder S
    J Clin Pharmacol; 2011 Jun; 51(6):805-18. PubMed ID: 20663996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Anticoagulant efficacy and safety of argatroban for patients undergoing elective percutaneous coronary intervention].
    Tian F; Yu H; Chen YD; Liu HB; Guo J; Sun ZJ; Jin QH; Yan F; Ma YL; Gu XF
    Zhonghua Xin Xue Guan Bing Za Zhi; 2013 Jun; 41(6):480-3. PubMed ID: 24113039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.
    Lewis BE; Matthai WH; Cohen M; Moses JW; Hursting MJ; Leya F;
    Catheter Cardiovasc Interv; 2002 Oct; 57(2):177-84. PubMed ID: 12357516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Argatroban for prevention and treatment of thromboembolism in heparin-induced thrombocytopenia.
    Kondo LM; Wittkowsky AK; Wiggins BS
    Ann Pharmacother; 2001 Apr; 35(4):440-51. PubMed ID: 11302409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of renal function on argatroban therapy during percutaneous coronary intervention.
    Hursting MJ; Jang IK
    J Thromb Thrombolysis; 2010 Jan; 29(1):1-7. PubMed ID: 19504050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of argatroban with or without glycoprotein IIb/IIIa inhibitor in patients with heparin induced thrombocytopenia undergoing percutaneous coronary intervention for acute coronary syndrome.
    Cruz-Gonzalez I; Sanchez-Ledesma M; Baron SJ; Healy JL; Watanabe H; Osakabe M; Yeh RW; Jang IK
    J Thromb Thrombolysis; 2008 Apr; 25(2):214-8. PubMed ID: 17632689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in high-risk patients undergoing percutaneous coronary intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty-Bivalirudin vs Heparin study).
    Patti G; Pasceri V; D'Antonio L; D'Ambrosio A; Macrì M; Dicuonzo G; Colonna G; Montinaro A; Di Sciascio G
    Am J Cardiol; 2012 Aug; 110(4):478-84. PubMed ID: 22583760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Argatroban versus heparin in patients without heparin-induced thrombocytopenia during venovenous extracorporeal membrane oxygenation: a propensity-score matched study.
    Fisser C; Winkler M; Malfertheiner MV; Philipp A; Foltan M; Lunz D; Zeman F; Maier LS; Lubnow M; Müller T
    Crit Care; 2021 Apr; 25(1):160. PubMed ID: 33910609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The direct thrombin inhibitor argatroban effectively prevents cardiac catheter thrombosis in vitro.
    Raaz U; Kaeberich A; Maegdefessel L; Buerke M; Busshardt M; Schubert S; Russ M; Plehn A; Ebelt H; Werdan K; Schlitt A
    Thromb Haemost; 2010 Apr; 103(4):808-14. PubMed ID: 20174756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia.
    Lewis BE; Wallis DE; Leya F; Hursting MJ; Kelton JG;
    Arch Intern Med; 2003 Aug 11-25; 163(15):1849-56. PubMed ID: 12912723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bleeding risk and outcomes of Bivalirudin versus Glycoprotein IIb/IIIa inhibitors with targeted low-dose unfractionated Heparin in patients having percutaneous coronary intervention for either stable or unstable angina pectoris.
    Steinberg DH; Shah P; Kinnaird T; Pinto Slottow TL; Roy PK; Okabe T; Bonello L; de Labriolle A; Smith KA; Torguson R; Xue Z; Suddath WO; Kent KM; Satler LF; Pichard AD; Lindsay J; Waksman R
    Am J Cardiol; 2008 Jul; 102(2):160-4. PubMed ID: 18602514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Argatroban and bivalirudin compared to unfractionated heparin in preventing thrombus formation on mechanical heart valves. Results of an in-vitro study.
    Maegdefessel L; Linde T; Michel T; Hamilton K; Steinseifer U; Friedrich I; Schubert S; Hauroeder B; Raaz U; Buerke M; Werdan K; Schlitt A
    Thromb Haemost; 2009 Jun; 101(6):1163-9. PubMed ID: 19492162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticoagulation for acute coronary syndromes: from heparin to direct thrombin inhibitors.
    Lepor NE
    Rev Cardiovasc Med; 2007; 8 Suppl 3():S9-17. PubMed ID: 17917621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial.
    Moliterno DJ;
    Catheter Cardiovasc Interv; 2011 Jun; 77(7):1001-9. PubMed ID: 21598351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unfractionated heparin administration in patients treated with bivalirudin during primary percutaneous coronary intervention is associated lower mortality and target lesion thrombosis: a report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).
    Koutouzis M; Lagerqvist B; James S; Omerovic E; Matejka G; Grip L; Albertsson P
    Heart; 2011 Sep; 97(18):1484-8. PubMed ID: 21487123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Argatroban anticoagulation in conjunction with glycoprotein IIb/IIIa inhibition in patients undergoing percutaneous coronary intervention: an open-label, nonrandomized pilot study.
    Jang IK; Lewis BE; Matthai WH; Kleiman NS
    J Thromb Thrombolysis; 2004 Aug; 18(1):31-7. PubMed ID: 15744551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Argatroban use during pediatric interventional cardiac catheterization.
    Cetta F; Graham LC; Wrona LL; Arruda MJ; Walenga JM
    Catheter Cardiovasc Interv; 2004 Jan; 61(1):147-9. PubMed ID: 14696176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.